News
Novartis (NOVN: VX) has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal hemoglobinuria (PNH) market and adding momentum to the oral drug’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results